345,314 Shares in Illumina, Inc. $ILMN Acquired by Patient Capital Management LLC

Patient Capital Management LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 345,314 shares of the life sciences company’s stock, valued at approximately $60,717,000. Illumina makes up approximately 2.0% of Patient Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Patient Capital Management LLC owned about 0.23% of Illumina as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at $32,000. Rakuten Securities Inc. purchased a new stake in Illumina in the second quarter valued at $33,000. Elyxium Wealth LLC acquired a new position in Illumina in the fourth quarter valued at $25,000. TD Waterhouse Canada Inc. acquired a new position in Illumina in the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Illumina in the fourth quarter valued at $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $219.40 on Monday. The company has a 50-day simple moving average of $188.01 and a 200-day simple moving average of $152.52. Illumina, Inc. has a one year low of $88.00 and a one year high of $220.43. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Activity

In other news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider directly owned 20,338 shares in the company, valued at $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,095,958 shares of company stock worth $401,720,974 in the last ninety days. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ILMN shares. TD Cowen boosted their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Guggenheim raised their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.